Free tool
FAERS Monitor: Pyrukynd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216196 or its brand name (Pyrukynd, Mitapivat Sulfate). Reports on generic versions are filed under their own applications.
Reports
1,331
Serious
199
15% of reports
Hospitalization
109
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemoglobin decreased230
- product dose omission issue197
- headache173
- fatigue159
- insomnia124
- off label use123
- nausea86
- arthralgia82
- drug ineffective76
- back pain64
- dizziness56
- asthenia52
- malaise51
- product dose omission in error51
- pain47
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 119 |
| 2023 | 182 |
| 2024 | 192 |
| 2025 | 217 |
| 2026 | 621 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemoglobin decreasedSignal | 230 | 35.5 | 31.5 | 7,691 |
| product dose omission in errorSignal | 51 | 28.5 | 21.8 | 1,326 |
| product dose omission issueSignal | 197 | 10.6 | 9.3 | 1,725 |
| insomniaSignal | 124 | 7.4 | 6.2 | 683 |
| headacheSignal | 173 | 4.4 | 3.8 | 458 |
| back painSignal | 64 | 4.4 | 3.4 | 164 |
| fatigueSignal | 159 | 3.2 | 2.8 | 252 |
| arthralgiaSignal | 82 | 3.1 | 2.5 | 118 |
| off label useSignal | 123 | 2.2 | 1.9 | 85 |
| astheniaSignal | 52 | 2.2 | 1.7 | 33 |
| malaise | 51 | 1.8 | 1.4 | 19 |
| dizziness | 56 | 1.8 | 1.4 | 19 |
| nausea | 86 | 1.7 | 1.4 | 26 |
| pain | 47 | 1.2 | 0.9 | 2 |
| drug ineffective | 76 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.